Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: chlorzoxazone, senicapoc | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 304 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4132
Sealed predictions
- KCNN4 in dopamine neurons, braak-0.26 (p 0.502) → -0.10 (p 0.807)receipt 4139
Swarm cases
receipt 4139: KCNN4 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.413, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.22 (p 0.384, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.125, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.413, n 18). fragile.
- cell type
- strongest in microglia: -0.63 (p 0.0051, n 18) vs -0.21 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KCNN4 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up KCNN4 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.55 p 0.051 (needs p < 4.8e-4)
Receipts
loading the receipts